# Coeptis Therapeutics Holdings, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Coeptis Therapeutics Holdings, Inc.).

## Overview

Coeptis Therapeutics Holdings, Inc. is a U.S.-based biopharmaceutical and technology holding company focused on acquiring, developing, and commercializing cell therapy technologies for cancer and other diseases. Through subsidiaries including Coeptis Therapeutics, Inc., SNAP Biosciences, Inc., and GEAR Therapeutics, Inc., it is shifting away from legacy generic drug activities toward innovative therapies and strategic development partnerships.

## Products & services

• Cell therapy technologies for cancer and other diseases
• Co-development programs for autoimmune and oncology therapies
• Legacy 505(b)(2) anti-hypertension drug products
• Strategic development and commercialization partnerships
• Biopharmaceutical IP and subsidiary platform management

- **Cell therapy technologies** (60%) — Development and commercialization of cell-based therapies targeting cancer and other diseases.
- **Strategic partnerships and co-development** (20%) — Collaborations to advance autoimmune and oncology assets with external partners.
- **Legacy pharmaceutical products** (5%) — Previously commercialized 505(b)(2) anti-hypertension products that have since been abandoned.
- **Platform and holding company activities** (15%) — Subsidiary oversight, IP ownership, and corporate development activities supporting the portfolio.

- Cell therapy technologies for cancer and other diseases
- Co-development programs for autoimmune and oncology therapies
- Legacy 505(b)(2) anti-hypertension drug products
- Strategic development and commercialization partnerships
- Biopharmaceutical IP and subsidiary platform management

## Customers

The company’s end customers are healthcare providers, patients, and ultimately payers in oncology, autoimmune, and other specialty disease markets. In practice, commercialization depends on partners, distributors, and marketing collaborators rather than a broad direct-sales model, reflecting its development-stage biopharma structure.

- **Oncology providers and treatment centers** (primary) — Buy or adopt cell therapy solutions for cancer care because they need differentiated treatment options.
- **Strategic pharmaceutical partners** (primary) — Partner on development and commercialization to share risk, expertise, and market access.
- **Autoimmune therapy collaborators** (secondary) — Work with the company on co-development programs for immune-mediated diseases.
- **Healthcare distributors and marketing partners** (secondary) — Support launch and promotion of products where the company lacks a large direct commercial footprint.

- Oncology treatment providers and institutions evaluating cell therapies
- Autoimmune disease partners seeking co-developed therapeutic assets
- Patients who would receive approved therapies through clinicians
- Commercial partners and marketers supporting product launch
- Payers and reimbursement systems that influence adoption

## Geography

The company states that its products and technologies are intended to be commercialized in the U.S. and other major markets worldwide, but the filings provided do not disclose a country revenue split. Operationally, it is U.S.-centered and exposed to U.S. regulatory, clinical, and commercialization requirements, with future expansion dependent on partner-led international market access.

- U.S. is the core operating and commercialization market
- Targets other major global markets through future commercialization
- No country-level revenue disclosure provided in the excerpts
- Regulatory and clinical execution are anchored in the United States
- International reach depends on partners and market approvals

## Strategy

Management is repositioning the company around innovative cell therapy and oncology-focused assets after exiting legacy generic and abandoned anti-hypertension products. The strategy relies on acquiring, developing, and partnering on differentiated technologies while building the subsidiary platform needed to support future commercialization.

- **Focus on cell therapy and oncology development** (medium-term) — These programs are the core of the company’s future value creation after exiting older product lines.
- **Expand strategic partnerships** (short-term) — Partnerships provide technical capability, funding leverage, and commercialization support for a small biopharma platform.
- **Build a scalable holding-company platform** (medium-term) — A structured subsidiary base helps manage IP, development programs, and future acquisitions.

- Shift capital away from legacy generic and abandoned products
- Advance cell therapy and oncology assets with strategic partners
- Build a portfolio of innovative therapies with broader market potential
- Use subsidiaries to organize development and commercialization efforts
- Pursue external partnerships to reduce development and launch risk

## Risks

The company faces typical development-stage biopharma risks, including clinical failure, regulatory delays, and difficulty converting scientific assets into commercial products. It also has company-specific execution risk from its history of abandoned products, reliance on partners, and the need to fund ongoing development while building a viable commercialization path.

- **Clinical development failure** [high] — Cell therapy and oncology assets may not demonstrate safety or efficacy in trials.
- **Regulatory approval delays** [high] — Biopharma products require extensive FDA and other regulatory review before commercialization.
- **Partner and commercialization execution risk** [medium] — The company relies on strategic partners for development and market access, reducing direct control.
- **Financing and dilution risk** [high] — Development-stage operations and professional fees can require repeated capital raises.

- Clinical and regulatory setbacks could delay or eliminate asset value
- Partner dependence can limit control over development and launch timing
- Prior product abandonment shows commercialization execution risk
- Cash burn and financing needs may pressure dilution and operations
- Small-company scale increases sensitivity to legal, consulting, and development costs

## Accounting

The filings highlight reverse-merger accounting history, which affects how the company’s financial statements are presented and compared across periods. Investors should also watch stock-based compensation, warrant-related financing costs, and professional-fee accruals, since these items can materially affect reported operating expenses and period-to-period comparability.

- **Reverse merger accounting** — Historical financial statements and trend analysis
- **Stock-based compensation** — Operating expenses and diluted share count
- **Warrant-related financing costs** — General and administrative expense and non-operating items
- **Professional fee accruals** — Quarterly expense volatility

- Reverse merger accounting affects historical comparability of results
- Stock-based compensation can materially move operating expenses
- Warrant expense and financing costs affect G&A volatility
- Professional fees tied to mergers and legal work can spike quarterly costs
- Development-stage spending creates judgment around expense timing

---

*Last updated: 2026-04-28T19:58:30.882582+00:00*